BS ISO 18362:2016+A1:2022

Manufacture of cell-based health care products. Control of microbial risks during processing. | Status: Current

1 Scope This International Standard specifies the minimum requirements for, and provides guidance on, a risk-based approach for the processing of cell-based health care products (CBHPs) requiring control of viable and non-viable microbial contamination. It is applicable both to CBHPs labelled 'sterile' and to CBHPs not labelled 'sterile'. This International Standard is not applicable to:

• — procurement and transport of cell-based starting material used in processing of a CBHP,
• — cell banking,
• — control of genetic material,
• — control of non-microbial product contamination,
• — in vitro diagnostics (IVDs), or
• — natural medicines.

EXAMPLE

Vitamins and minerals, herbal remedies, homoeopathic medicines, traditional medicines such as traditional Chinese medicines, probiotics, other products such as amino acids and essential fatty acids. This International Standard does not define biosafety containment requirements. Text deleted. .